Johns Hopkins logo

Health Newsfeed

NO MORE AVASTIN

THE FDA HAS DECIDED AVASTIN ISN’T INDICATED IN ADVANCED BREAST CANCER, ELIZABETH TRACEY REPORTS

Avastin, a blockbuster drug for Genentech for treatment of colon cancer and other types of cancer, is no longer FDA approved to treat advanced breast cancer, the agency announced recently.  Ben Park, a breast cancer expert at Johns Hopkins, says this is the right choice.

PARK:  Further studies have come out and they have not reproduced the same effect in terms of progression free survival, and so now the FDA has looked at all the clinical data out there on Avastin in advanced breast cancer and decided, based on the real minimal benefit, the high cost of the drug and the potential side effects, which are not trivial and include things like bleeding, clotting, high blood pressure, sometimes heart failure, the FDA has really done the right thing and reviewed ongoing data that has now matured and decided maybe this doesn’t merit using in advanced breast cancer anymore.  :35

At Johns Hopkins, I’m Elizabeth Tracey.


Search Health NewsFeed

-----------------------------------------
Health NewsFeed Home | Hopkins Medicine Home